NCT02734004 2026-04-20
MEDIOLA
AstraZeneca
Phase 1/2 Active not recruiting
Clinical Trials
15 trialsNCT07340164 2026-04-20
TROY
Yonsei University
Phase 2 Recruiting
NCT07213804 2026-04-17
FRAmework-01
Eli Lilly and Company
Phase 3 Recruiting
NCT06824467 2026-04-16
TroFuse-022
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT07318558 2026-04-16
TroFuse-021
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT05039801 2026-04-15
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT06906341 2026-04-14
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Corcept Therapeutics
Phase 2 Recruiting
NCT02839707 2026-04-13
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
NCT05183984 2026-04-13
NIRVANA-1
ARCAGY/ GINECO GROUP
Phase 2 Recruiting
NCT05739981 2026-04-13
MRD
Imunon
Phase 1/2 Recruiting
NCT06787612 2026-04-08
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Regeneron Pharmaceuticals
Phase 2 Recruiting
NCT07225270 2026-04-08
RAINFOL-04
Genmab
Phase 3 Recruiting
NCT05579366 2026-04-07
RAINFOL-01
Genmab
Phase 1/2 Recruiting
NCT04938583 2026-04-06
Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer
CanariaBio Inc.
Phase 1/2 Active not recruiting
NCT02873962 2026-04-01
A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib
Dana-Farber Cancer Institute
Phase 2 Active not recruiting